Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer
Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer
复制标题
DOI：
10.1002/ijc.11009
复制
发表时间：
2003-05-10
影响因子：
6.4
通讯作者：
Birner, P
中科院分区：
文献类型：
--
作者：
Schoppmann, SF;Schindl, M;Birner, P
Id-I是细胞生长和分化的重要调节剂，并控制乳腺癌细胞的恶性进展。我们研究的目的是评估乳腺癌中Id-I表达的临床影响，即，其对预后和治疗反应预测的潜在影响。采用免疫组化法检测191例淋巴结阴性乳腺癌患者Id-I蛋白表达，并进行单因素和多因素生存分析。Id-I强表达15例（7.9%），中表达75例（39.3%），弱表达55例（28.8%），阴性46例（24.1%）。与不表达或低表达的患者相比，Id-I强表达或中度表达的患者总体（p = 0.003，考克斯回归）和无病生存期（p = 0.01，考克斯回归）显著缩短。与中度/强表达的乳腺癌相比，在Id-I表达缺失/低的乳腺癌中，预后因子受体密度显著更高（p < 0.001，t检验）。Id-I表达在p16（INK 4a）表达阳性的病例中显著强于p16表达阴性的病例（p = 0.049，Mann-Whitney检验）。Id-I对临床结果的影响似乎更强的雌激素受体阴性的患者相比，那些具有积极的状态，谁收到受体拮抗剂作为辅助治疗，在大多数情况下。Id-I蛋白的过表达是淋巴结阴性乳腺癌的一个强有力的独立预后标志物，未来抑制Id-I表达的治疗可能对这些患者有益。我们的研究结果还表明，由于Id-I与乳腺癌中的类固醇受体系统的明显相互作用，激素治疗可能会影响Id-I的表达及其对临床结果的影响。(C)2003 Wiley-Liss，Inc.
Id-I is an important regulator of cellular growth and differentiation and controls malignant progression of breast cancer cells. The aim of our study was to assess the clinical impact of Id-I expression in breast cancer, i.e., its potential impact on prognosis and prediction of treatment response. Id-I protein expression was determined immunohistochemically in 191 patients with lymph-node negative breast cancer, and univariate and multivariate survival analysis was carried out. Fifteen (7.9%) specimens showed strong expression, 75 (39.3%) moderate, 55 (28.8%) weak expression and 46 (24.1%) cases no expression of Id-I. Patients with strong or moderate Id-I expression had a significant shorter overall (p = 0.003, Cox regression) and disease-free survival (p = 0.01, Cox regression) compared to those with absent or low expression. Progesterone receptor density was significantly higher in breast cancers with absent/low Id- I expression compared to those with moderate/strong expression (p < 0.001, t-test). Id-I expression was significantly stronger in cases positive for p16(INK4a) expression compared to those negative for p 16 (p = 0.049, Mann-Whitney test). The influence of Id-I on clinical outcome seems much stronger in patients with negative estrogen receptor status compared to those with positive status, who received receptor antagonists as adjuvant therapy in most cases. Overexpression of Id-I protein represents a strong independent prognostic marker in node negative breast cancer, and future therapies inhibiting Id-I expression might be beneficial for these patients. Our results also suggest that due to the apparent interaction of Id-I with the steroid-receptor system in breast cancer, hormonal therapies might influence Id-I expression and its impact on clinical outcome. (C) 2003 Wiley-Liss, Inc.